Key Highlights
- Sun Pharmaceutical Industries delivered a binding, all-cash $12 billion acquisition proposal for Organon (OGN)
- Shares of OGN climbed 41% to $8.25 on Friday, following an 18% increase to $6.91 on Thursday
- Sun Pharma wrapped up more than three months of comprehensive due diligence and is securing financing through JPMorgan and MUFG
- The transaction would represent the most significant cross-border M&A deal ever executed by an Indian pharmaceutical firm
- Shares of Sun Pharmaceutical declined 3% in Mumbai trading after the announcement
Organon’s shares experienced a remarkable two-day surge. The New Jersey-headquartered women’s healthcare specialist rocketed 41% higher on Friday morning to reach $8.25, building on the previous day’s 18% advance, following disclosure that Sun Pharmaceutical Industries had presented a formal $12 billion acquisition proposal.
India’s Economic Times broke the story, revealing that the Mumbai-headquartered pharmaceutical manufacturer had progressed past the due diligence phase and submitted a binding, all-cash proposal. Sun Pharma has dedicated over three months to developing this transaction.
Organon’s present market capitalization stands at approximately $1.8 billion, positioning the $12 billion proposal as a significant premium above its existing valuation.
The deal’s funding structure involves collaboration with prominent financial institutions. JPMorgan and Japan’s MUFG rank among the international banks facilitating Sun Pharma’s capital arrangements.
Organon’s Corporate History
Organon emerged as an independent entity through a Merck spinoff in 2021. The company concentrates on reproductive health, contraception, and fertility treatments, while maintaining additional product lines in dermatology, neurology, and cardiovascular therapies.
The organization has navigated challenging circumstances recently. CEO Kevin Ali departed in October 2025 following an internal board review that uncovered what the company characterized as inappropriate sales tactics employed to artificially boost quarterly performance.
Sun Pharma’s pursuit of Organon has surfaced previously. The Economic Times reported in January that Sun Pharma had presented a non-binding, all-cash proposal and was gearing up to commence due diligence. Friday’s disclosure represents significant advancement from that preliminary phase.
Implications for Sun Pharma
Successful completion of this transaction would establish it as the most substantial international acquisition in the history of Indian pharmaceutical companies — setting a new industry benchmark.
Sun Pharmaceutical shares responded unfavorably to the disclosure, falling 3% in Mumbai trading on Friday. Such market responses frequently occur when acquiring entities announce substantial, debt-financed transactions.
Both Organon and Sun Pharmaceutical declined to provide statements to media inquiries at the time of publication.
OGN had been experiencing subdued trading levels prior to this week’s dramatic movement. The consecutive gains of 18% and 41% signal a substantial transformation in investor perception regarding the stock.
As of Friday morning, Sun Pharma has reportedly reached the concluding phases of the proposal process, with financing arrangements being secured concurrent with the binding offer.
